Risk-Benefit Assessment of Drug Treatment to Prevent Coronary Heart Disease Estimating the Benefits of Risk Factor Modification
- 期刊名称Drug Safety
- 作者Dr Steven A. Grover,Louis Coupal
- 卷第10卷
- 期第4期
- 印刷ISSN0114-5916
- 电子ISSN1179-1942
- 文件大小1329.81KB
- 发表时间1994-04
- DOI10.2165/00002018-199410040-00004
- 页码301-309
Nicotinic acid: clinical considerationsKei, Anastazia; Elisaf, Moses S · Expert Opinion on Drug Safety · 2012
Drug safety evaluation of rosuvastatinToth, Peter P; Dayspring, Thomas D · Expert Opinion on Drug Safety · 2011
Gastrointestinal side effects of drugsMakins, Richard; Ballinger, Anne · Expert Opinion on Drug Safety · 2003
Capecitabine and hand–foot syndromeSaif, Muhammad Wasif · Expert Opinion on Drug Safety · 2011
Immune hemolytic anemia caused by drugsGarratty, George · Expert Opinion on Drug Safety · 2012
Benfluorex-induced cardiac valve injuryAcar, Jean · Pharmacoepidemiology and Drug Safety · 2012
Extrapyramidal Symptoms with Atypical AntipsychoticsPierre, Joseph M · Drug Safety · 2005
Tolerability of ParacetamolGraham, Garry G; Scott, Kieran F; Day, Richard O · Drug Safety · 2005